Apr 10, 2018
AbbVie Corporation et al v Samsung Bioepis Co. Ltd.
Featuring: Benjamin Reingold, Peter Wilcox and Marian Wolanski
We represented AbbVie in a series of eight applications under the Patented Medicines (Notice of Compliance) Regulations relating to AbbVie’s blockbuster drug HUMIRA. The cases related to four different patents and were among the first in Canada relating to a subsequent entry biologic (biosimilar) drug. These cases were settled during the cross-examination phase as part of a global settlement between AbbVie and Samsung Bioepis.